HAIFA, Israel, Feb. 16 /PRNewswire/ -- InSightec today announced that its ExAblate(R) 2000 system was highlighted as one of Advanced Imaging's '2005 Imaging Solutions of the Year' in its recent issue. Recently approved by the U.S. Food and Drug Administration for the non-invasive surgery of symptomatic uterine fibroids, the system is currently in use around the world for the treatment of uterine fibroids and clinical trials are underway for both benign and cancerous tumors such as breast fibroadenoma, breast cancer, brain tumors, bone tumors and liver tumors. This is the third time the Company has been recognized for its MRgFUS technology. Other awards include the 2004 Grand Prize by the European Union's Information Society Technology and the Bronze Medal in Wall Street Journal 2004 Technology Innovation Award competition. "ExAblate 2000 offers a patient-friendly uterine-sparing outpatient treatment for women with symptomatic uterine fibroids," Dr. Jacob Vortman, president and CEO, InSightec said. "Advanced Imaging's recognition reiterates the importance of this breakthrough technology as a non-invasive surgical procedure that will allow patients to return quickly to normal life. ExAblate is the first FDA approved system to use focused ultrasound for therapy and MRI imaging for real time control of the treatment." ExAblate(R) 2000 is the first system to combine Magnetic Resonance Imaging (MRI) with high-intensity focused ultrasound to thermally ablate (destroy) tissue without any incisions. ExAblate 2000 was approved by the FDA in October 2004 after it was granted an expedited review because of the significant advantages afforded by this technology over existing treatments for uterine fibroids. ExAblate 2000 is compatible only with General Electric Healthcare's SIGNA Magnetic Resonance systems. Currently, nine major medical centers in the United States are equipped with the ExAblate 2000 System: -- Brigham and Women's Hospital in Boston, MA. -- The Johns Hopkins Hospital in Baltimore, MD -- Mayo Clinic in Rochester, MN -- University MRI in Boca Raton, FL -- Tower Beverly Radiology - Radnet in Beverly Hills, CA -- Virtua Health in Voorhees, NJ -- The Lahey Clinic in Burlington, MA -- Cornell Weill Medical Center, New York, NY -- UCSD Medical Center in San Diego, California Systems are also installed in London, Berlin, Tel Aviv, and in several locations in Japan. Physicians, patients or hospital administrators interested in learning more about ExAblate 2000 for the treatment of symptomatic uterine fibroids may call 1-866-EXABLATE. Patient information is also available at http://www.uterine-fibroids.org. About InSightec InSightec Image Guided Treatment Ltd. is a privately held company owned by Elbit Medical Imaging (EMI), General Electric, private investors and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 100 employees and has invested more than $60 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com For more information contact: InSightec http://www.insightec.com Tel: +972-4-813-1329 Email: email@example.com For media inquiries, contact: Laura Yoshida Phone: +1-212-867-1762 Email: firstname.lastname@example.org
SOURCE InSightec Ltd.